BR112018069023A2 - métodos de tratamento de doenças colestáticas - Google Patents

métodos de tratamento de doenças colestáticas

Info

Publication number
BR112018069023A2
BR112018069023A2 BR112018069023A BR112018069023A BR112018069023A2 BR 112018069023 A2 BR112018069023 A2 BR 112018069023A2 BR 112018069023 A BR112018069023 A BR 112018069023A BR 112018069023 A BR112018069023 A BR 112018069023A BR 112018069023 A2 BR112018069023 A2 BR 112018069023A2
Authority
BR
Brazil
Prior art keywords
treatment methods
disease treatment
cholestatic disease
cholestatic
carboxidimethylmethyloxyphenyl
Prior art date
Application number
BR112018069023A
Other languages
English (en)
Inventor
Hanf Rémy
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112018069023A2 publication Critical patent/BR112018069023A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere ao uso do composto 1-[4-metiltiofenil]-3-[3,5-dimetil-4-carboxidimetilmetiloxifenil]prop-2-en-1-ona (elafibranor ou gft505) para tratar doenças colestáticas, e mais especificamente pbc e/ou psc.
BR112018069023A 2016-03-31 2017-03-30 métodos de tratamento de doenças colestáticas BR112018069023A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305381 2016-03-31
PCT/EP2017/057634 WO2017167935A1 (en) 2016-03-31 2017-03-30 Methods of treatment of cholestatic diseases

Publications (1)

Publication Number Publication Date
BR112018069023A2 true BR112018069023A2 (pt) 2019-01-29

Family

ID=55661352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069023A BR112018069023A2 (pt) 2016-03-31 2017-03-30 métodos de tratamento de doenças colestáticas

Country Status (15)

Country Link
US (1) US11185519B2 (pt)
EP (2) EP3435996A1 (pt)
JP (1) JP7010836B2 (pt)
KR (1) KR102338085B1 (pt)
CN (2) CN114796237B (pt)
AU (1) AU2017242819B2 (pt)
BR (1) BR112018069023A2 (pt)
CA (1) CA3018132C (pt)
EA (1) EA038386B1 (pt)
IL (2) IL311687A (pt)
MX (2) MX2018011738A (pt)
PH (1) PH12018502056A1 (pt)
SG (1) SG11201808222RA (pt)
WO (1) WO2017167935A1 (pt)
ZA (1) ZA201807084B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
US20220133666A1 (en) * 2016-03-31 2022-05-05 Genfit Methods of treatment of cholestatic diseases
JP2020510651A (ja) * 2017-02-24 2020-04-09 ジェンフィＧｅｎｆｉｔ 併用療法のための医薬組成物
US20200283381A1 (en) * 2017-11-16 2020-09-10 Teva Pharmaceuticals International Gmbh Solid state forms of elafibranor
WO2019186410A1 (en) * 2018-03-27 2019-10-03 Lupin Limited Solid forms of elafibranor and processes thereof
EP3863623A1 (en) * 2018-10-11 2021-08-18 Centre national de la recherche scientifique Treatment of diseases associated with biliary system destruction
WO2020167958A1 (en) * 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
US11291661B2 (en) * 2019-03-13 2022-04-05 Novartis Ag Pharmaceutical composition
CN110548118B (zh) * 2019-10-21 2021-09-14 江苏省中医院 一种具有防治原发性胆汁性胆管炎的中药复方及其制备方法与应用
AU2021220519A1 (en) * 2020-02-10 2022-09-22 Genfit Treatment of primary biliary cholangitis with elafibranor
CN115605192A (zh) * 2020-05-18 2023-01-13 基恩菲特公司（Fr） 用于治疗原发性硬化性胆管炎的伊拉非布拉诺尔
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
WO2023225334A1 (en) * 2022-05-19 2023-11-23 Tyra Biosciences, Inc. Therapies with ppar agonists and fgfr4 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
MX2012006062A (es) * 2009-11-26 2012-06-28 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para el tratamiento de trastornos hepaticos.
CA2976056C (en) * 2015-02-06 2024-02-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
JP2020510651A (ja) * 2017-02-24 2020-04-09 ジェンフィＧｅｎｆｉｔ 併用療法のための医薬組成物

Also Published As

Publication number Publication date
CN114796237A (zh) 2022-07-29
AU2017242819B2 (en) 2022-06-30
PH12018502056A1 (en) 2019-07-01
CN109152756B (zh) 2022-05-17
EA201892202A1 (ru) 2019-03-29
CN109152756A (zh) 2019-01-04
CA3018132C (en) 2024-02-13
EP3435996A1 (en) 2019-02-06
EP4233910A3 (en) 2024-01-17
IL261935B1 (en) 2024-05-01
IL311687A (en) 2024-05-01
IL261935A (en) 2018-10-31
MX2021015783A (es) 2022-12-09
AU2017242819A1 (en) 2018-10-11
US20190111012A1 (en) 2019-04-18
ZA201807084B (en) 2019-06-26
US11185519B2 (en) 2021-11-30
EA038386B1 (ru) 2021-08-19
CN114796237B (zh) 2024-02-23
SG11201808222RA (en) 2018-10-30
KR102338085B1 (ko) 2021-12-10
JP2019510046A (ja) 2019-04-11
MX2018011738A (es) 2019-06-24
CA3018132A1 (en) 2017-10-05
JP7010836B2 (ja) 2022-01-26
KR20180126574A (ko) 2018-11-27
EP4233910A2 (en) 2023-08-30
WO2017167935A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
BR112018069023A2 (pt) métodos de tratamento de doenças colestáticas
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2019012233A (es) Anticuerpos anti-sirpa.
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2022007522A (es) Anticuerpos anti-cd27.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
TW201613901A (en) New compounds
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
TR201819042T4 (tr) Fibrozis ve kanserlerin tedavisine yönelik yöntemler.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EA202091619A2 (ru) Антитела против tigit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]